Multimodal gene and targeted drug therapy for chronic myelogenous leukemia using BIM/MCL-1 chimeric nanoparticle: computational target analysis and therapeutic validation. This evidence concerns the gene MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive.